Forteo (teriparatide; Eli Lilly) is a recombinant N-terminal fragment (amino acids 1–34) of human parathyroid hormone (PTH). Endogenous PTH plays a central role in the regulation of calcium and phosphate metabolism in mammals and acts to regulate bone remodeling. PTH is a direct anabolic agent in bone tissue and acts to stimulate the formation of new bone by activating osteoblasts. The 34 N-terminal amino acids contained in Forteo are the biologically active region of PTH, and Forteo has the same biological functions. Forteo acts to increase skeletal mass and bone strength and is not detrimental to the skeleton, unlike a continuous excess of endogenous PTH.
LIST OF FIGURES
12 Figure 1: Forteo for osteoporosis – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Forteo for osteoporosis
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Forteo for osteoporosis
LIST OF TABLES
5 Table 1: Forteo drug profile
7 Table 2: Forteo pivotal trial data in osteoporosis
10 Table 3: Forteo late-phase trial data in osteoporosis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.